Publications

Detailed Information

Change in Antibiotic Resistance of Helicobacter pylori Strains and the Effect of A2143G Point Mutation of 23S rRNA on the Eradication of H-pylori in a Single Center of Korea

DC Field Value Language
dc.contributor.authorHwang, Tae Jun-
dc.contributor.authorKim, Nayoung-
dc.contributor.authorKim, Hong Bin-
dc.contributor.authorLee, Byoung Hwan-
dc.contributor.authorPark, Ji Hyun-
dc.contributor.authorPark, Young Soo-
dc.contributor.authorJung, Hyun Chae-
dc.contributor.authorSong, In Sung-
dc.contributor.authorLee, Dong Ho-
dc.contributor.authorLee, Mi Kyoung-
dc.contributor.authorNam, Ryoung Hee-
dc.date.accessioned2012-06-27T06:47:31Z-
dc.date.available2012-06-27T06:47:31Z-
dc.date.issued2010-09-
dc.identifier.citationJOURNAL OF CLINICAL GASTROENTEROLOGY; Vol.44 8; 536-543ko_KR
dc.identifier.issn0192-0790-
dc.identifier.urihttps://hdl.handle.net/10371/77611-
dc.description.abstractBackground: The current prevalence of primary antibiotic resistance of H. pylori is not known in Korea. This study was done to evaluate the prevalence of primary antibiotic resistance of H. pylori, and to evaluate the effect of point mutations of 23S rRNA on the rate of eradication of H. pylori. Methods: H. pylori were isolated from gastric mucosal biopsy specimens obtained from 222 Koreans. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, ciprofloxacin, and levofloxacin were examined using the agar dilution method. DNA sequencing was carried out to detect H. pylori 23S rRNA mutations. Results: The resistance to clarithromycin, tetracycline, ciprofloxacin, and levofloxacin increased during the period of 2007 to 2009 compared with 2003 to 2005 (P < 0.05). However, amoxicillin and metronidazole resistance slightly decreased. The rates of eradication were 95.5% for the clarithromycin-sensitive strains, which was higher than the 67.9% for the clarithromycin-resistant strains (P = 0.001). By contrast, the eradication rate was 100% in patients with amoxicillin-resistant H. pylori. Among 26 clarithromyin-resistant strains, 6 (23%) had A2143G mutations, and all of the cases in which these mutations were present were not eradicated by proton pump inhibitor-based triple therapy (P = 0.0004). By contrast, none of the 26 clarithromyin-sensitive strains had A2143G mutations. The T2183C and A2223G mutations were frequently found in the sensitive strains and in the resistant strains. Conclusions: Clarithromycin resistance of H. pylori, which determined the efficacy of H. pylori eradication of proton pump inhibitor triple regimen, was found to be increased in a single center study. A2143G was an important 23S rRNA mutation associated with clarithromycin resistance and affected the H. pylori eradication efficacy.ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectHelicobacter pyloriko_KR
dc.subjectantibioticsko_KR
dc.subjectpointko_KR
dc.subjectclarithromycinko_KR
dc.subjectresistanceko_KR
dc.subjectmutationko_KR
dc.titleChange in Antibiotic Resistance of Helicobacter pylori Strains and the Effect of A2143G Point Mutation of 23S rRNA on the Eradication of H-pylori in a Single Center of Koreako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor황태준-
dc.contributor.AlternativeAuthor김나영-
dc.contributor.AlternativeAuthor김홍빈-
dc.contributor.AlternativeAuthor이병환-
dc.contributor.AlternativeAuthor남령희-
dc.contributor.AlternativeAuthor박지현-
dc.contributor.AlternativeAuthor이미경-
dc.contributor.AlternativeAuthor박영수-
dc.contributor.AlternativeAuthor이동호-
dc.contributor.AlternativeAuthor정현채-
dc.contributor.AlternativeAuthor송인성-
dc.identifier.doi10.1097/MCG.0b013e3181d04592-
dc.citation.journaltitleJOURNAL OF CLINICAL GASTROENTEROLOGY-
dc.description.citedreferenceKim JM, 2008, J MICROBIOL BIOTECHN, V18, P1584-
dc.description.citedreferenceMegraud F, 2007, CLIN MICROBIOL REV, V20, P280, DOI 10.1128/CMR.00033-06-
dc.description.citedreferenceBANG SY, 2007, KOREAN J GASTROENTER, V50, P356-
dc.description.citedreferenceGerrits MM, 2006, LANCET INFECT DIS, V6, P699-
dc.description.citedreferenceLee K, 2006, YONSEI MED J, V47, P634-
dc.description.citedreferenceKim N, 2006, J CLIN GASTROENTEROL, V40, P683-
dc.description.citedreferenceKim JM, 2006, INT J ANTIMICROB AG, V28, P6, DOI 10.1016/j.ijantimicag.2006.02.015-
dc.description.citedreferenceDe Francesco V, 2006, ANN INTERN MED, V144, P94-
dc.description.citedreferenceKIM SJ, 2006, HORTIC ENVIRON BIOTE, V47, P349-
dc.description.citedreferenceKim JM, 2005, J ANTIMICROB CHEMOTH, V56, P965, DOI 10.1093/jac/dki334-
dc.description.citedreferenceKIM YJ, 2005, INFECT CHEMOTHERAPY, V37, P271-
dc.description.citedreferenceKim JM, 2004, ANTIMICROB AGENTS CH, V48, P4843, DOI 10.1128/AAC.48.12.4843-4847.2004-
dc.description.citedreferenceFujimura S, 2004, J MED MICROBIOL, V53, P1019, DOI 10.1099/jmm.0.45642-0-
dc.description.citedreferenceMegraud F, 2004, GUT, V53, P1374, DOI 10.1136/gut.2003.022111-
dc.description.citedreferenceMegraud F, 2004, DRUGS, V64, P1893-
dc.description.citedreferenceTankovic J, 2003, ANTIMICROB AGENTS CH, V47, P3942, DOI 10.1128/AAC.47.12.3942-3944.2003-
dc.description.citedreferenceEun CS, 2003, J GASTROENTEROL, V38, P436, DOI 10.1007/s00535-002-1079-2-
dc.description.citedreferenceDailidiene D, 2002, ANTIMICROB AGENTS CH, V46, P3940, DOI 10.1128/AAC.46.12.3940-3946.2002-
dc.description.citedreferenceSuerbaum S, 2002, NEW ENGL J MED, V347, P1175-
dc.description.citedreferenceKim KS, 2002, J KOREAN MED SCI, V17, P599-
dc.description.citedreferenceLing TKW, 2002, HELICOBACTER, V7, P327-
dc.description.citedreferenceWolle K, 2002, J MED MICROBIOL, V51, P705-
dc.description.citedreferenceMalfertheiner P, 2002, ALIMENT PHARM THERAP, V16, P1-
dc.description.citedreferenceEltahawy AT, 2002, MED PRIN PRACT, V11, P65-
dc.description.citedreferenceSharara AI, 2002, INT J ANTIMICROB AG, V19, P155-
dc.description.citedreferencePoon SK, 2002, ALIMENT PHARM THERAP, V16, P291-
dc.description.citedreferenceEcclissato C, 2002, HELICOBACTER, V7, P53-
dc.description.citedreferenceKato S, 2002, J CLIN MICROBIOL, V40, P649, DOI 10.1128/JCM.40.2.649-653.2002-
dc.description.citedreference*NAT COMM CLIN LAB, 2002, M100S12 NCCLS-
dc.description.citedreferenceGlupczynski Y, 2001, EUR J CLIN MICROBIOL, V20, P820, DOI 10.1007/s100960100611-
dc.description.citedreferenceOsato MS, 2001, ARCH INTERN MED, V161, P1217-
dc.description.citedreferenceKato M, 2000, ANTIMICROB AGENTS CH, V44, P2214-
dc.description.citedreferenceMendonca S, 2000, HELICOBACTER, V5, P79-
dc.description.citedreferenceMaeda S, 2000, J CLIN MICROBIOL, V38, P210-
dc.description.citedreferenceDebets-Ossenkopp YJ, 1999, J ANTIMICROB CHEMOTH, V43, P511-
dc.description.citedreferenceLind T, 1999, GASTROENTEROLOGY, V116, P248-
dc.description.citedreferenceDore MP, 1999, J ANTIMICROB CHEMOTH, V43, P47-
dc.description.citedreferenceAdamek RJ, 1998, AM J GASTROENTEROL, V93, P386-
dc.description.citedreferenceDAVID YG, 1998, GASTROENTEROLOGY, V115, P1272-
dc.description.citedreferenceOcchialini A, 1997, ANTIMICROB AGENTS CH, V41, P2724-
dc.description.citedreferenceTaylor DE, 1997, ANTIMICROB AGENTS CH, V41, P2621-
dc.description.citedreferenceVersalovic J, 1997, J ANTIMICROB CHEMOTH, V40, P283-
dc.description.citedreferenceStone GG, 1997, ANTIMICROB AGENTS CH, V41, P712-
dc.description.citedreference1994, J AM MED ASS, V272, P65-
dc.description.citedreferenceMARSHALL BJ, 1984, LANCET, V1, P1311-
dc.description.tc5-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share